Oramed again.

Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin

"Mannkind Corp. (MNKD), however, has not given up on inhalable insulin and continues its multi-billion dollar effort to create Afrezza, a smaller, easier to use version of Exubera. It's not without problems - in January 2010, the FDA refused completion of the device's application review process because the company did not supply sufficient data on upgrades of the inhaler's design -- an amateurish mistake, in my opinion. In 2011, the FDA sent Mannkind a complete response letter -- the agency's official "no way" -- based on unclear drug performance data, how the device is used, how it will be labeled, packaged, shipped and stored, and incomplete safety information. For the $2 billion-plus it's costing to bring Afrezza to market, you would think these are questions Alfred Mann could answer in his sleep."

http://seekingalpha.com/article/1445881-oramed-sweeps-past-worldwide-giants-with-the-first-trial-of-orally-delivered-insulin?source=nasdaq

For those who haven't heard of Oramed,it's been discussed here before.

http://agoracom.com/ir/Mannkind/forums/discussion/topics/539130-our-competion